Complete remission with romidepsin in a patient with T‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|340-343

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 340-343

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

One acute promyelocytic leukemia patient underwent complete molecular remission with consistent presence of t (2; 3) (p25; q21) karyotype

By You Yong He Yanli Zou Jing Zheng Jine Chen Lei Li Xiaoqing Zou Ping Zhang Min

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 10, 2013-10 ,pp. : 1115-1118

Informa Healthcare

Access to resources Recommend Favorite

Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer

By Taghdisi Seyed Mohammad Abnous Khalil Mosaffa Fatemeh Behravan Javad

Journal of Drug Targeting, Vol. 18, Iss. 4, 2010-05 ,pp. : 277-281

Informa Healthcare

Access to resources Recommend Favorite

Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia: Current and Emerging Treatments

By Martin Alissa Morgan Elaine Hijiya Nobuko

Pediatric Drugs, Vol. 14, Iss. 6, 2012-12 ,pp. : 377-387

Adis International

Access to resources Recommend Favorite

Romidepsin: In the Treatment of T-Cell Lymphoma

By Yang Lily P.H.

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1469-1480

Adis International

Access to resources Recommend Favorite

Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia

By Thomas Xavier

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 6, 2012-06 ,pp. : 871-878

Informa Healthcare

Access to resources Recommend Favorite